跳至主要内容
临床试验/JPRN-UMIN000021931
JPRN-UMIN000021931已完成未知

Pilot Study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer - FINEX Pilot Study

Kanagawa children's medical center0 个研究点目标入组 12 人开始时间: 2016年4月18日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 18years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Active infection controls. Congenital or Acquired immunodeficiency syndrome AIDS . Determined ineligible by doctor.

研究者

发起方
Kanagawa children's medical center

相似试验

已完成
不适用
Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancerhepatoblastoma and hepatocellular carcinoma of children
JPRN-UMIN000022324Kanagawa Children's Medical Center12
进行中(未招募)
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)
EUCTR2009-012576-27-PLMedical Faculty, University Magdeburg710
进行中(未招募)
1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMICCarcinoma hepatocelular (CHC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 12.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellular
EUCTR2009-012576-27-SIMedical Faculty, University Magdeburg665
进行中(未招募)
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)
EUCTR2009-012576-27-ATMedical Faculty, University Magdeburg710
进行中(未招募)
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 16.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864
EUCTR2009-012576-27-NLMedical Faculty, University Magdeburg665